Kura Oncology Inc is a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer... Show more
KURA is expected to report earnings to fall 2.73% to -72 cents per share on October 30
Q3'25
Est.
$-0.73
Q2'25
Missed
by $0.34
Q1'25
Missed
by $0.04
Q4'24
Beat
by $0.35
Q3'24
Est.
$-0.63
The last earnings report on August 07 showed earnings per share of -75 cents, missing the estimate of -40 cents. With 2.56M shares outstanding, the current market capitalization sits at 664.00M.
These past five trading days, the stock lost 0.00% with an average daily volume of 0 shares traded.The stock tracked a drawdown of 0% for this period. KURA showed earnings on August 07, 2025. You can read more about the earnings report here.